Boston Scientific (BSX) reported $20.1B in revenue for fiscal 2025, +19.9% year on year. That ranks #279 by revenue among 2853 SEC filers and #33 in Healthcare. Net income was $2.9B, a net margin of 14.4%. Revenue has grown 8.5% a year on average since 2012 ($7.0B then). The fiscal 2025 balance sheet shows $43.7B in total assets, $2.0B in cash and $11.1B in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $20.1B | +19.9% | FY20252025-12-31 |
| Gross profitGrossProfit | $13.9B | +20.6% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | $3.6B | +38.8% | FY20252025-12-31 |
| Net incomeProfitLoss | $2.9B | +56.7% | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $4.5B | +32.0% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $876M | +10.9% | FY20252025-12-31 |
| Total assetsAssets | $43.7B | +10.9% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $24.2B | +11.3% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $2.0B | +374.6% | FY20252025-12-31 |
| Long-term debtLongTermDebtAndCapitalLeaseObligations | $11.1B | +24.2% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $5.2B | $1.3B | Open → |
| Q2 20262026-06-30 | $5.4B | $905M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Where this sits in its sector
Each bar is the spread of the whole sector: the box covers the middle half of companies, the line inside it the median, and the triangle this company. The axis is clipped at the 5th and 95th percentile so a single outlier does not flatten it.
| Where this sits in its sector | FY2025 | Position in sector |
|---|---|---|
| Net marginRank 41 of 161 companies compared | 14.4% | |
| Operating marginRank 43 of 160 companies compared | 18.0% | |
| R&D as share of revenueRank 44 of 102 companies compared | 10.2% | |
| Cash as share of revenueRank 84 of 160 companies compared | 9.8% |
All four are ratios derived from two reported lines, not single filing items. Peer group: companies in the same sector with revenue of $1bn or more; loss-making companies are included.
Profile
- Legal name
- Boston Scientific Corp
- Ticker
- BSX
- Exchange
- NYSE
- SIC classification
- Surgical & Medical Instruments & Apparatus (3841)
- Fiscal year end
- 12-31
- CIK
- 0000885725
Filings
- 10-QAug 3, 2026Open filing →
- 10-QMay 1, 2026Open filing →
- 10-KFeb 17, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Tenet HealthcareTHC | $21.3B | $2.4B |
| GE Healthcare TechnologiesGEHC | $20.6B | $2.1B |
| Koninklijke PhilipsPHG | $20.2B | $1.0B |
| Boston ScientificBSX | $20.1B | $2.9B |
| Universe PharmaceuticalsUPC | $17.9B | −$3.7B |
| Universal Health ServicesUHS | $17.4B | $1.5B |
| Teva Pharmaceutical IndustriesTEVA | $17.3B | $1.4B |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Boston Scientific — Key figures |url=https://companiesranked.com/en/company/boston-scientific |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Boston Scientific — Key figures. CompaniesRanked. https://companiesranked.com/en/company/boston-scientificBibTeX
@misc{companiesranked-en-company-boston-scientific-2026,
author = {{CompaniesRanked}},
title = {{Boston Scientific — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/boston-scientific}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0000885725-26-000010 · February 17, 2026
{{cite web |title=Boston Scientific — Key figures — 10-K (0000885725-26-000010) |url=https://www.sec.gov/Archives/edgar/data/885725/000088572526000010/bsx-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-17}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.